Spots Global Cancer Trial Database for Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Official Title: Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy

Study ID: NCT02657785

Conditions

Primary Central Nervous System Lymphoma

Interventions

R-IDARAM plus intrathecal chemotherapy

Study Description

Brief Summary: This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

Detailed Description: The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in primary central nervous system lymphoma (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.